RadioGel™ is a next-generation
#cancer
treatment for tumors in humans.
#PRnT
is currently undergoing review with the
@US_FDA
. A trademark brand of
@VivosIncUSA
Markets are back open Tuesday. Until then, we're wishing all our shareholders and followers a safe long weekend; with a reflective
#MartinLutherKingJr
holiday Monday.
#MartinLutherKingDay
$RDGL
Update –
#IsoPet
®
#Cancer
Therapy was performed on Jackie, a Staffordshire-Terrier, Lab mix
#dog
with a large tumor on the right paw. What is noteworthy is the Pet Parent's insurance company approved the procedure.
The tumor has decreased in size & the
#pet
is doing well. $RDGL
Hard to believe one week ago was New Year's Day. In the past week we've had an increased in interest in
#RadioGel
™ and Vivos.
Here is a handy infographic that clearly shows the key benefits of our multi-patented device technology and how it differs in the marketplace. $RDGL
1). Jan 20, 2022
@HopkinsMedicine
treated their first pet with
#IsoPet
® therapy.
Francis previously had a high-grade soft tissue sarcoma removed from his left forelimb in Nov 2021. IsoPet® was utilized to treat the surgical 'dirty' margins surrounding the treatment area.
Skin
#Cancer
was selected as our first indication of use for
#RadioGel
™ to the FDA. Proven effective in killing cancer cells; it also has notable advantages over existing therapies. The potential market in
#humans
is just a beginning...
#CancerAwareness
#savinglives
#hope
$rdgl
In any worthwhile endeavor... the quality relationships and partners that you establish along the way; are what ultimately add to its success. Thank you to all the people and
#pets
that have trusted in us this far. Tomorrow is a new month.
#RadioGel
™
#IsoPet
®
#CancerResearch
We have a team of dedicated scientists who are passionate about a next generation cancer treatment and have made RadioGel™ their top priority. The road to IDE submission will end and saving lives will begin!
#CancerResearch
#Cancer
@VivosIncUSA
$RDGL
The new site is live!
@RadioGel
needs to focus on human cancer (we are not approved for human cancer yet),
@IsoPetForCancer
is our animal cancer division and
@VivosIncUSA
is our corporation. It's all coming together! Thank you all for your patience! $RDGL
1). We're pleased to share the latest update on Yukon from her pet parents. Yukon was treated July 24, 2020:
"She continues to do well, and the tumor on her leg continues to shrink. I would say it is about 1/2 the size from the last visit and the open sore has healed.
We've had a lot of interest with our pending
@US_FDA
Breakthrough Application for
#human
#Cancer
treatment. However; it's important to remember RadioGel™ is readily available for
#PetCancer
therapy.
IsoPet® therapy online application:
$RDGL
#petlovers
Exactly 1 week from today, Dr. Mike Korenko along with University of Missouri Veterinary Health Center oncologist Dr. Charles Maitz, will be taking center stage in Louisville, Kentucky to present successful results from our Canine testing with IsoPet®.
#cancertreatment
#research
2/2 – Conference organizers allotted him twice the normal time to present. The slide presentation employed both English and Japanese translation throughout.
Participants asked many good questions, and overall, expressed strong interest in the information presented.
$RDGL
With Covid-19 restrictions easing, we're expecting to handle more
#IsoPet
® treatment requests. In addition, we've been receiving interest from foreign companies with inquiries into prospective collaborative ventures regarding the potential uses of
#RadioGel
™.
#Cancer
$RDGL
We've received an overwhelming amount of support today; along with numerous questions. This short animation on the Patented
@IsoPet
® |
@RadioGel
™ process is worth sharing over & over. Thank you. YTTRIUM 90 RADIOGEL™ BRACHYTHERAPY DEVICE $RDGL
Animal
#IsoPet
® therapy applied to a
#cancer
tumor begins by mixing our multi-patented Yttrium-90 HydroGel (
#RadioGel
™) with the water soluble polymer. Once injected at the markers; the tumor is destroyed over time with no collateral damage to adjacent tissue.
#PetCancer
$RDGL
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The
@US_FDA
advised using different product names in order to avoid confusion and cross-use.
#IsoPet
®
#RadioGel
™
1/2. Annie from Colorado, was one of our first post Covid-19
#pets
treated at the University of Missouri
@MUCVM
.
#IsoPet
® Therapy was performed August 5, 2021 on a soft tissue sarcoma.
We enjoy sharing Pet Parent updates with our shareholders and followers.
#petlives
$RDGL
Receiving an 'IDE' for
#RadioGel
™ will allow
#human
clinical trials to begin. The data we’ve collected through
#IsoPet
® usage will form part of the pre-submission. Our target is Q2-2021.
A Breakthrough Device Approval may expedite this process.
$RDGL
Let’s keep Wellness Wednesday going.
#IsoPet
keeps doing what some people once called impossible.
From our team at Vista. “It's going well. Dr. Gobble said the Pathologist said the sample that he sent in showed no signs of Blast Cells.” Very positive!
#Cancers
#pets
#dogs
$RDGL
Update –
#IsoPet
®
#Cancer
Therapy was performed on Jackie, a Staffordshire-Terrier, Lab mix
#dog
with a large tumor on the right paw. What is noteworthy is the Pet Parent's insurance company approved the procedure.
The tumor has decreased in size & the
#pet
is doing well. $RDGL
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the FDA has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device.$RDGL
One of the most promising fields developing in
#CancerResearch
is 'combination therapy'. The power of synergistic treatments may be able to accomplish more than just one.
#immunotherapy
combined with radiation treatment has exciting possibilities.
#Cancertreatment
#savinglives
"I'm still here, and I will do whatever it takes to fight." Natalie Wells has terminal brain cancer, but she's determined to stay around to raise her two young daughters.
#fightcancer
#cancersucks
#cancerwarrior
This is what our team is working so hard on these past few months, we are advocating for our revolutionary cancer treatment to be approved. We will update as new information becomes available! $RDGL
To learn more read the blog at
We've been referencing this path in our News Releases over the past year. Treating animals first is what lead to the registered brand
#IsoPet
®. It has also provided us with the critical data to move forward on another goal – Saving
#human
lives. Thank you.
We’re diligently working towards being one of the ‘trusted providers’ when it comes to discussing tumor treatment options.
#CancerResearch
#CancerTreatment
$RDGL
People diagnosed with rare brain and spine tumors, and researchers who study them, face unique challenges. NCI-CONNECT intends to address those challenges head on. Find out how.
#NothingWillStopUs
#CancerCare
Today is an important
#milestone
for Vivos & reflects the efforts of numerous parties. In particular, we're pleased that this IDE filing included the Mayo Clinic Clinical Trial Protocol for
#RadioGel
™, which is currently being reviewed by Mayo’s Independent Review Team. $RDGL
Numerous have asked; we're answering. "An important difference of RadioGel™ to older
#brachytherapy
products is, the minimally invasive radiation that is emitted to adjacent healthy tissue. We have achieved a very high therapeutic index in our animal testing.
What makes
@RadioGel
™ unique? Our Beta emitter technology. It delivers a high dose of localized radiation that does not travel far; thus minimizing collateral damage to healthy tissue. This is in complete opposite to most other
#brachytherapy
products that still utilize Gamma.
Great news worth sharing this Saturday morning from Facebook regarding Moose. "Hallelujah!!! No visible soft tissue sarcoma tumors! Final official report is in from 1 year since diagnosis! Clear chest Xray! Clear lymph nodes! Perfect blood work!" $RDGL
It’s a
#Milestone
!
A three (3) year process to receive an invaluable
#patent
for manufacturing the hydrogel component for our
#RadioGel
™ &
@IsoPet_RadioGel
Therapies has been achieved.
Congratulations to our Team.
Mike Korenko Sc. D - CEO • President Vivos, Inc.
$RDGL
You may have seen a
@Facebook
Blog setup by the owner of the 2nd canine in our trials. Pam has been gracious to track & share the progress of 'Moose'. Great to have additional feedback outside the visits to see Dr. Maitz
@MUCVM
#petcancerawarenessmonth
|
1/2 – July 8, 2021, Dr. Darrell Fisher, Vivos Inc’s medical physicist; delivered his invited paper by virtual link-up at the Japan Radioisotope Association Annual Meeting on
#IsoPet
therapy. The title was “Radionuclide Therapy of Solid Tumors by Direct Interstitial Injection.”
What is the science behind RadioGel™ and how does Y-90 play a role in the treatment of cancer? Read the blog and subscribe to our newsletter to read the latest as we prepare to submit the IDE for RadioGel™ to be used for human cancer trials.
#Cancer
$RDGL
RadioGel™ is one of the two divisions
@VivosIncUSA
@IsoPetForCancer
has been treating animals with cancer since 2018 and is expanding!
The IDE will be submitted for human cancer trials in Q2.
has the latest information $RDGL
IDE Update - the team
@VivosIncUSA
is carefully reviewing the IDE application to submit to the FDA. An investigational device exemption (IDE) allows the device to be used in a clinical study in order to collect safety and effectiveness data.
#Cancer
$RDGL
1/2). We're pleased to share another
#IsoPet
® update on our favourite Lab, Yukon.
"Yukon continues to do well. Tumor continues to shrink ! She eats well and healthy. Getting older – she will be 10 in July – so she has slowed down ... not quite as fast in frisbee toss...
Good day. As per our timeline review with our
@US_FDA
Breakthrough Device application; late yesterday $RDGL received word from the Agency for clarification on one of the Criterion. This dialogue was anticipated and we're responding accordingly before the due date.
Thank you.
(1/2). As part of our
@FDA
IDE application process the first 'pre-submission' meeting for
#RadioGel
™ is scheduled for November 30, 2021. The FDA recommended this path to facilitate enhanced ongoing communication with Vivos and to increase the efficiency of the review process.
Today is an important
#milestone
for Vivos & reflects the efforts of numerous parties. In particular, we're pleased that this IDE filing included the Mayo Clinic Clinical Trial Protocol for
#RadioGel
™, which is currently being reviewed by Mayo’s Independent Review Team. $RDGL
Dr. Korenko is busy packing his bags, to begin making his way across the country to Louisville, Kentucky for the VCS Conference. He'll be speaking at 9:00 am EST Saturday, October 20th. Once again here is link to our news about attending the event.
#IsoPet
Lots of questions on where our website went, it was all part of the plan to have people visit our new corporate site The rebranding is a process so please be patient with us!
#CancerTreatment
#RadioGel
#IsoPet
#VivosIncUSA
$RDGL
Although we did not receive 'fast tracking' approval in regards to our 'Breakthrough Device"
#RadioGel
™, we're performing additional testing to hit our Early Summer '21 target of submission for our IDE with the
@US_FDA
.
$RDGL
#CancerResearch
#Cancer
Our primary focus in the coming New Year will be securing the Investigational Device Exemption ("IDE") from the
@US_FDA
for our multi-patented
#RadioGel
™
#brachytherapy
device; and continue to plan for future
#human
clinical trials.
#Cancer
will be beaten.
$RDGL
#breakthrough
Vivos Inc Obtains Feedback from the FDA on Clinical Testing of
#RadioGel
™.
November 30 Vivos Inc. met with the
@US_FDA
to obtain suggestions on improving the current draft of the IDE for
#Human
Clinical Trials.
#Cancer
#CancerTreatment
$RDGL
(2/2). This review typically takes several iterations and we will continue with biocompatibility testing in parallel.
This filing is an important milestone for Vivos and reflects the efforts of numerous parties. We will share updates of the process when possible.
Thank you.
Late today we submitted our response to the
@US_FDA
comments on our application for Breakthrough Device Designation for
#RadioGel
™. This was a substantial effort involving our entire team and three
@MayoClinic
doctors working over the holidays.
1/2 “This effort has been substantial over the last several months, and is an invaluable investment necessary to transform our company into a serious commercial entity that has the potential to treat both animal and humans both domestically & internationally."
$RDGL
#RadioGel
™
2/2). Here is the latest update from Annie's Parent:
"Dear Dr. Korenko: Annie is actually doing really well! The tumor is gone now, and the wound is healing well. Here is a video of her running again."
#Cancer
#petlives
#dogsoftwitter
#dogs
#dogs
#CancerResearch
$RDGL
Always nice to have one of our favorite Poster Ready Canine's hamming it up for the camera. Moose is still alive and kicking, and enjoying life to the fullest thanks to IsoPet®. $RDGL
#petlives
#dogsoftwitter
#Cancer
Follow his journey on Facebook at
We're continually asked, "What
#Cancers
will your multi-patented
#RadioGel
™
#brachytherapy
be able to treat."
Here's our list of
#Cancers
our Advisory Board believe we'll be able to safely treat.
#IsoPet
® is currently being applied successfully on
#pet
skin cancer. $RDGL
Introducing our CEO Mike Korenko to our loyal followers. Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
#VivosIncUSA
$RDGL
1/2... We're pleased to share Dr. Darrell Fisher's Peer Reviewed Article on Y-90
#IsoPet
® is the highest downloaded article in the Journal in 2020. "Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite"
Link:
At Conventions, posters are made to demonstrate a product, or process. Our
#IsoPet
® poster is almost 5' wide; utilizing results from our recent successful
#canine
tests. Shortly, we'll be converting it into a slide show & placing on our website.
#CancerAwareness
#CancerTreatment
We're receiving growing requests for
#IsoPet
® Therapy throughout the US, Canada and other countries. We're working through this Covid-19 pandemic to offer more Regional accessibility to this treatment in the coming year.
#Cancer
#savinglives
#pets
#animals
$RDGL
We’re pleased to share an update regarding our
@US_FDA
IDE pre-submission process with
#RadioGel
™.
We’ve formally requested the next FDA meeting and submitted our proposed Animal Test Plan.
Thank you.
Update:
#cancers
#cancer
#nextgeneration
$RDGL
Reminder... January is
#ThyroidAwarenessMonth
.
Utilizing
#RadioGel
™ device technology; we're working to have diseased Thyroids saved, versus removed. $RDGL
January is
#ThyroidAwarenessMonth
. The thyroid gland is a vital hormone gland. Mayo Clinic's Thyroid Disorders Specialty Group provides comprehensive consultations for patients with thyroid disease or those with suspected thyroid disorder.
@MayoClinicEndo
"I believe that
#veterinary
oncologists around the Globe will finally have an ideal product line for the treatment of accessible and inoperable tumors." – Dr. Alive Villalobos | Chair of the Vivos Inc. Veterinary Medical Advisory Board
#pets
#cancertreatment
#WorldAnimalDay
RadioGel™ is not a drug. It's a next-generation multi patented medical device that involves injecting a proprietary
#yttrium
-90 (90Y) gel into a solid tumor, effectively killing the
#Cancer
.
$RDGL
#CancerResearch
RadioGel™ is an yttrium-90 (90Y) based injectable Precision Radionuclide Therapy (PRnT)® medical device for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Our multi-patented Precision Radionuclide Therapy (PRnT)® uses highly localized
Cancer is only getting more prevalent and as technology advances, we are excited to be part of the fight against cancer. We are dedicated to saving lives worldwide! The future is coming and we will be ready!
#VivosIncUSA
#RadioGel
#IsoPet
#Cancer
$RDGL
More
#IsoPet
updates: "Yukon's tumor continues to get smaller. The open sore has healed. She is doing well – appetite and activity both good. Thanks again – Happy Holidays and continued success with the clinical trials!" Steve & Kathy (Pet Parents).
$RDGL
#pets
#dogs
#cancerfree
... pre-submission meeting so we can now move ahead to the next level of review.
With all the criticism directed toward the
@US_FDA
I have to say they have done an excellent job in helping us navigate this process and focus our efforts.
Thank you.
Dr. M Korenko.
$RDGL
Dr. Korenko and our team have been diligently working to improve
#RadioGel
through continual testing so that we can be one of these ‘exciting new technologies’ in the marketplace.
$RDGL
#Cancer
#CancerResearch
#savinglives
"We've seen consistent and meaningful declines in cancer mortality, and exciting new technologies, across the spectrum from prevention to diagnosis to survivorship."
#AACR21
Wow. One just had to look at that Ballpark this evening to see we've all been affected in someway by
#Cancer
...our Team included. We have a lot of desire to bringing our treatment(s) to patients worldwide. If we can reach the
#Tumor
; we can kill it.
#savinglives
#CancerResearch
Another touching placard moment during tonight’s
#WorldSeries
game where thousands held placards to share who they stand up for.
Help us reach our goal of $15,000 to help create a world with more long-term survivors. Donate here: .
This past year we selected one of the largest medical isotope suppliers in the world, Eckert & Zieglar Radiopharma () for Yttrium-90 (Y-90) utilized in our multi-patented formalization of
#RadioGel
™ |
#IsoPet
®
#brachytherapy
.
$RDGL
#Cancer
#Biotechnology
As we ramp up to open the RadioGel™️ division
@VivosIncUSA
this study connects why our
@IsoPetForCancer
division is so important. We are saving pets with our cutting edge
#cancer
treatment and humans will be next! $RDGL